medigraphic.com
Colegio de Medicina Interna de México.

2020, Number 5

<< Back Next >>

Med Int Mex 2020; 36 (5)

Pseudomembranous colitis, a problem in Mexico. Report of an outbreak and its control

Casanova-Cardiel LJ, Ornelas-Corral L, Vega-Nájera CA, Galindo-Parra JA, Castañeda-Echeverría M

Language: Spanish
References: 29
Page: 716-721
PDF size: 246.45 Kb.


ABSTRACT

Abstract: Pseudomembranous colitis is a serious problem worldwide; despite scarce local reports, Mexico does not seem to escape from it. In order to share our experience, we report an outbreak of this entity and the control measures carried out at a Regional Hospital of the IMSS in Ciudad Juarez, Chihuahua.
Clinical cases: From an index case in 2010 (rate 2.09 per 10,000 patient days), during the months of February to July 2011, 12 similar cases were presented (rate of 5.89 cases per 10,000 patient days), with a significant predominance of female sex (11 of 13); the average age corresponded to the elderly population (62.8 years); diabetes mellitus 2 was the underlying condition (11 of 13 patients); long time of evolution of diabetes (16.25 years on average). The most prescribed antibiotics were third generation cephalosporins, quinolones and clindamycin. Omeprazole was prescribed in all patients. Two patients underwent colectomy and one exploratory laparotomy in one patient, with the death of these three patients. Mortality was 62% (8 of 13 patients). After taking various measures the outbreak ceased.
Conclusions: The outbreak reported shows the needed surveillance, prevention and control measures that have to be done in all hospitals of the country that attend patients requiring hospitalization.


REFERENCES

  1. Burke JP. Infection control-A problem for patient safety. N Engl J Med 2003; 348: 651-6. doi: 10.1056/NEJMhpr020557

  2. Yokoe DS, Classen D. Improving patient safety through infection control: A new health care imperative. Infect Control Hosp Epidemiol 2008; 29: S3-11. doi: 10.1086/591063

  3. Pittet D, Donaldson M. Clean care is safer care: The first global challenge of the WHO world alliance for patient safety. Infect Control Hosp Epidemiol 2005; 26: 891-4.

  4. Pittet D, Allegranzy B, Storr J, Nejad SB, Dziekan G, Leotzakos A, Donaldson M. Infection control as a major World Health Organization priority for developing countries. J Hosp Infect 2008; 68: 285-92. doi: 10.1016/j. jhin.2007.12.013

  5. Haley RW, Culver DH, White JW, Morgan WM, Emori TG, Munn VP, Hooton TM. The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospital. Am J Epidemiol 1985; 121: 182-205. DOI: 10.1093/oxfordjournals.aje.a113990

  6. Dirección General de Epidemiología. Red Hospitalaria de Vigilancia Epidemiológica (RHOVE). Secretaría de Salud. México 2016 (http://187.191.75.115/gobmx/salud/documentos/ manuales/28_Manual_RHoVE.pdf)

  7. Bartlett JG. Narrative Review: The new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006; 145: 758-64. doi: 10.7326/0003-4819-145-10- 200611210-00008

  8. Kilgore G, Thompson A, Johnson S, et al. Comparison of Seven techniques for typing international epidemic strains of Clostridium difficile: Restriction endonuclease analysis, pulsed-field gel electrophoresis, PCR-ribotyping, multilocus sequence typing, multilocus variable-number tandemrepeat analysis, amplified fragment length polymorphism, and surface layer protein a gene sequence typing. J Clin Microbiol 2008; 46: 431-7. doi: 10.1128/JCM.01484-07

  9. Solana LJ, Aguilera E, Vinageras JI, Perez MJ. Colitis pseudomembranosa: Presentación de cuatro casos. Rev Gastroenterol Mex 1997; 62: 113-6.

  10. Camacho-Ortiz A, Ponce-de-León S, Sifuentes-Osornio J. Enfermedad asociada a Clostridium difficile en América Latina. Gac Med Mex 2009; 145: 223-9.

  11. Camacho-Ortiz A, Galindo-Fraga A, Rancel-Cordero A, et al. Factores asociados con el desarrollo de la enfermedad por Clostridium difficile en un hospital de tercer nivel en México: estudio de casos y controles. Rev Invest Clin 2009; 61: 371-7.

  12. Ruiz AJD, Motta RGA, Rodríguez TC, González SCB. Colitis pseudomembranosa (CPM). Acta Med Gpo Ángeles 2010; 8: 221-2.

  13. Ramírez-Rosales A, Cantú-Llanos A. Mortalidad intrahospitalaria en pacientes con diarrea asociada a infección por Clostridium difficile. Rev Gastroenterol Mex 2012; 77: 60-5. DOI: 10.1016/j.rgmx.2012.04.001

  14. Motta-Ramírez GA, Torres-Montoya JM, Martínez-Utrera MJ, Rebollo-Hurtado V, Guizar-López GU. Diagnóstico por imagen seccional de la colitis pseudomembranosa. Anales de Radiología México 2015; 14: 43-65.

  15. Sierra-Hernández A, Estrada-Hernández LO. Antibiótico más relacionado con colitis por antimicrobianos en pacientes hospitalizados. Med Int Mex 2016; 32: 330-40.

  16. Martínez-Rodríguez AA, Estrada-Hernández LO, Tomé-Sandoval P, Salazar-Salinas J. Diarrea por Clostridium difficile en pacientes hospitalizados. Med Int Mex 2018; 34: 9-18. https://doi.org/10.24245/mim.v34i1.1921

  17. Dial S, Delaney JAC, Barkun AN, Suissa S. Use of gastric acidsuppressive agents and the risk of community-acquired Clostridium difficile-associated infection. JAMA 2005; 294 (23): 2989-95. doi: 10.1001/jama.294.23.2989

  18. Kwok CS, Arthur AK, Anibueze CI. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012; 107: 1101-9. doi: 10.1038/ajg.2012.108

  19. Zacharioudakis I, Zervou F, Pliakos E, Mylonakis E. Colonization with toxinogenic C. difficile upon hospital admission, and risk of infection: A systematic review and meta-analysis. Am J Gastroenterol 2015; 110: 381-90. doi: 10.1038/ajg.2015.22

  20. Trifan A, Stanciu C, Girleanu I, et al. Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis. World J Gastroenterol 2017; 23: 6500-15. doi: 10.3748/wjg.v23.i35.6500

  21. Avendaño-Reyes JM. Administración de inhibidores de la bomba de protones como factor de riesgo de infección por Clostridium difficile: ¿mito o realidad? Med Int Mex 2016; 32: 561-8.

  22. Villatoro MA, Carrasco NM, Sánchez GMT. Uso inapropiado de la terapia antisupresora gástrica en urgencias. Arch Med Urg Mex 2012; 4: 6-12.

  23. Forgacs I. Overprescribing proton pump inhibitors. Is expensive and not evidence based. BMJ 2008; 336: 2-3. doi: 10.1136/bmj.39406.449456.BE

  24. Villafuerte-Gálvez JA, Kelly CP. Proton pump inhibitors and risk of Clostridium difficile infection: association or causation? Curr Opin Gastroenterol 2018; 34: 11-18. doi: 10.1097/MOG.0000000000000414

  25. Tariq R, Singh S, Gupta A, Pardi DS, Khanna S. Association of gastric acid suppression with recurrent Clostridium difficile Infection. A systematic review and meta-analysis. JAMA Intern Med 2017; 177: 784-91. doi: 10.1001/jamainternmed. 2017.0212

  26. Miller M, Gravel D, Mulvey M, et al. Health care-associated Clostridium difficile infection In Canada: Patient age and infecting strain type are highly predictable of severe outcome and mortality. Clin Infect Dis 2010; 50: 194-201. doi: 10.1086/649213

  27. Loo VG, Bourgault A-M, Poirier L. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011; 365: 1693-703.

  28. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update for the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Cont Hosp Ep 2010; 31: 431-55.

  29. McDonald LC, Gerding DN, Johnson S. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018; 66: e1-e48. https:// doi.org/10.1093/cid/cix1085




2020     |     www.medigraphic.com